Evidence map›Paper›PMID 35664997›Full record

ArticlemedRxiv : the preprint server for health sciences2022

Impact of a blood-stage vaccine on

Mimi M Hou, Jordan R Barrett, Yrene Themistocleous, Thomas A Rawlinson, Ababacar Diouf, Francisco J Martinez, Carolyn M Nielsen, Amelia M Lias, Lloyd D W King, Nick J Edwards and 25 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

35 authors at 7 institutions in 5 countries.

Mimi M HouDepartment of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.
Jordan R BarrettDepartment of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.
Yrene ThemistocleousThe Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
Thomas A RawlinsonThe Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
Ababacar DioufLaboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA.
Francisco J MartinezUnité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, 25-28 Rue du Dr Roux, 75015 Paris, France.
Carolyn M NielsenDepartment of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.
Amelia M LiasDepartment of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.
Lloyd D W KingDepartment of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.
Nick J EdwardsThe Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
Nicola M GreenwoodThe Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
Lucy KinghamThe Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
Ian D PoultonThe Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
Baktash KhozoeeThe Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
Cyndi GohThe Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
Dylan J Mac LochlainnDepartment of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.
Jo SalkeldDepartment of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.
Micheline Guilotte-BlisnickUnité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, 25-28 Rue du Dr Roux, 75015 Paris, France.
Christèle HuonUnité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, 25-28 Rue du Dr Roux, 75015 Paris, France.
Franziska MohringDepartment of Infection Biology, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK.
Jenny M ReimerNovavax AB, Kungsgatan 109, SE-753 18, Uppsala, Sweden.
Virander S ChauhanInternational Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India.
Paushali MukherjeeMulti-Vaccines Development Program, New Delhi, India.
Sumi BiswasThe Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
Iona J TaylorThe Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
Alison M LawrieThe Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
Jee-Sun ChoDepartment of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.
Fay L NugentThe Jenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
Carole A LongLaboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA.
Robert W MoonDepartment of Infection Biology, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK.
Kazutoyo MiuraLaboratory of Malaria and Vector Research, NIAID/NIH, Rockville, MD 20852, USA.
Sarah E SilkDepartment of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.
Chetan E ChitnisUnité de Biologie de Plasmodium et Vaccins, Institut Pasteur, Université Paris Cité, 25-28 Rue du Dr Roux, 75015 Paris, France.
Angela M MinassianDepartment of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.
Simon J DraperDepartment of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK.
University of Oxford · GBInstitut Pasteur · FRVector Oncology (United States) · USLondon School of Hygiene & Tropical Medicine · GBInternational Centre for Genetic Engineering and Biotechnology · INMulti Vaccines Development Program · INNovavax (Sweden) · SE

Funding

Medical Research Council G1100086Medical Research Council MC_PC_16056Medical Research Council MR/M021157/1Wellcome Trust
6 · The paper itself

Abstract

Background: There are no licensed vaccines against Methods: We conducted two Phase I/IIa clinical trials to assess the safety, immunogenicity and efficacy of two vaccines targeting region II of Results: Thirty-two volunteers were enrolled and vaccinated (n=16 for each vaccine). No safety concerns were identified. PvDBPII/Matrix-M™, given in the delayed dosing regimen, elicited the highest antibody responses and reduced the mean PMR following CHMI by 51% (range 36-66%; n=6) compared to unvaccinated controls (n=13). No other vaccine or regimen impacted parasite growth. Conclusions: Vaccination of malaria-naïve adults with a delayed booster regimen of PvDBPII/ Matrix-M™ significantly reduces the growth of blood-stage

Identifiers

PMID35664997
PMCPMC9164524
OpenAlexW4282031838

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.